Detection meter and mode of operation Patent Grant Emery , et al. May 2, 2 [Emery; Jeffrey L.]

Detection meter and mode of operation

Emery , et al. May 2, 2

Patent Grant 9636051

U.S. patent number 9,636,051 [Application Number 12/457,331] was granted by the patent office on 2017-05-02 for detection meter and mode of operation. This patent grant is currently assigned to Intuity Medical, Inc.. The grantee listed for this patent is Jeffrey L. Emery, Charles Hu, Michael F. Tomasco. Invention is credited to Jeffrey L. Emery, Charles Hu, Michael F. Tomasco.

United States Patent	9,636,051
Emery , et al.	May 2, 2017

Detection meter and mode of operation

Abstract

A method for performing an assay to determine the presence or concentration of an analyte contained in a sample of body fluid by using a device comprising at least one analyte quantification member and a sensor associated therewith, the method includes: applying a first sample to the analyte quantification member; and detecting the presence or absence of an adequate sample volume; wherein upon detection of the absence of an adequate sample volume, initiating a finite timed period, and signaling the user to introduce a second sample of body fluid to the analyte quantification member. Associated arrangements and devices are also disclosed.

Inventors:

Emery; Jeffrey L. (Redwood City, CA), Tomasco; Michael F. (Los Altos, CA), Hu; Charles (Sunnyvale, CA)

Applicant:

Name	City	State	Country	Type
Emery; Jeffrey L. Tomasco; Michael F. Hu; Charles	Redwood City Los Altos Sunnyvale	CA CA CA	US US US

Assignee:

Intuity Medical, Inc. (Sunnyvale, CA)

Family ID:

41398408

Appl. No.:

12/457,331

Filed:

June 8, 2009

Prior Publication Data


	Document Identifier	Publication Date
	US 20100021947 A1	Jan 28, 2010

Related U.S. Patent Documents


Application Number	Filing Date	Patent Number	Issue Date
61129149	Jun 6, 2008

Current U.S. Class:	1/1
Current CPC Class:	A61B 5/150396 (20130101); A61B 5/150022 (20130101); A61B 5/157 (20130101); A61B 5/15163 (20130101); A61B 5/150099 (20130101); A61B 5/150358 (20130101); A61B 5/15113 (20130101); A61B 5/150503 (20130101); A61B 5/15109 (20130101); A61B 5/14532 (20130101); A61B 5/150809 (20130101); A61B 5/150755 (20130101); A61B 5/150954 (20130101); A61B 5/150824 (20130101); A61B 5/1455 (20130101); A61B 2562/0295 (20130101); A61B 5/1468 (20130101); A61B 2560/0276 (20130101)
Current International Class:	G01N 33/00 (20060101); A61B 5/157 (20060101); A61B 5/151 (20060101); A61B 5/15 (20060101); A61B 5/145 (20060101); A61B 5/1455 (20060101); A61B 5/1468 (20060101)

References Cited [Referenced By]

U.S. Patent Documents


842690	January 1907	Oswalt
D137874	May 1944	Partridge
2749797	March 1950	Harks
3092465	June 1963	Adams, Jr.
3310002	March 1967	Wilburn
3620209	November 1971	Kravitz
3623475	November 1971	Sanz et al.
3626929	December 1971	Sanz et al.
3630957	December 1971	Rey
D223165	March 1972	Komendat
3723064	March 1973	Liotta
3741197	June 1973	Sanz et al.
3961898	June 1976	Neeley et al.
4014328	March 1977	Cluff et al.
4042335	August 1977	Clement
4057394	November 1977	Genshaw
4109655	August 1978	Chacornac
4250257	February 1981	Lee et al.
4254083	March 1981	Columbus
4258001	March 1981	Pierce et al.
4260257	April 1981	Neeley et al.
4289459	September 1981	Neeley et al.
4321397	March 1982	Nix et al.
4350762	September 1982	DeLuca et al.
4394512	July 1983	Batz
4414975	November 1983	Ryder et al.
4416279	November 1983	Lindner et al.
4418037	November 1983	Katsuyama et al.
4422941	December 1983	Vaughan, Jr. et al.
4429700	February 1984	Thees et al.
4627445	December 1986	Garcia et al.
4637403	January 1987	Garcia et al.
4637406	January 1987	Guinn et al.
4653513	March 1987	Dombrowski
4661319	April 1987	Lape
4702261	October 1987	Cornell et al.
4711250	December 1987	Gilbaugh, Jr. et al.
4737458	April 1988	Batz et al.
4767415	August 1988	Duffy
4774192	September 1988	Terminiello et al.
4790979	December 1988	Terminiello et al.
4794926	January 1989	Munsch et al.
4815843	March 1989	Tiefenthaler et al.
4829470	May 1989	Wang
4846785	July 1989	Cassou et al.
4887306	December 1989	Hwang et al.
4920977	May 1990	Haynes
4930525	June 1990	Palestrant
4935346	June 1990	Phillips
4953552	September 1990	De Marzo
4966646	October 1990	Zdeblick
4995402	February 1991	Smith
5029583	July 1991	Meserol
5049487	September 1991	Phillips et al.
5050617	September 1991	Columbus et al.
5059394	October 1991	Phillips et al.
5077199	December 1991	Basagni et al.
5094943	March 1992	Siedel et al.
5116759	May 1992	Klainer et al.
5131404	July 1992	Neeley et al.
5141868	August 1992	Shanks et al.
5145565	September 1992	Kater et al.
5146437	September 1992	Boucheron
5153416	October 1992	Neeley
5164575	November 1992	Neeley et al.
5166498	November 1992	Neeley
5174291	December 1992	Schoonen et al.
5176632	January 1993	Bernardi
5179005	January 1993	Phillips et al.
5183741	February 1993	Arai et al.
5196302	March 1993	Kidwell
5208163	May 1993	Charlton et al.
5213966	May 1993	Vuorinen et al.
5217480	June 1993	Haber et al.
5218966	June 1993	Yamasawa
5223219	June 1993	Subramanian et al.
5234818	August 1993	Zimmermann et al.
5241969	September 1993	Carson et al.
5251126	October 1993	Kahn et al.
D341848	November 1993	Bigelow et al.
5275159	January 1994	Griebel
5278079	January 1994	Gubinski et al.
5288646	February 1994	Lundsgaard et al.
5299571	April 1994	Mastrototaro
5301686	April 1994	Newman
5302513	April 1994	Mike et al.
5304468	April 1994	Phillips et al.
5306623	April 1994	Kiser et al.
5308767	May 1994	Terashima
5320607	June 1994	Ishibashi
5354537	October 1994	Moreno
5360595	November 1994	Bell et al.
5368047	November 1994	Suzuki et al.
5383512	January 1995	Jarvis
5390671	February 1995	Lord et al.
5399316	March 1995	Yamada
5401110	March 1995	Neeley
5402798	April 1995	Swierczek et al.
5441513	August 1995	Roth
5451350	September 1995	Macho et al.
5458140	October 1995	Eppstein et al.
5460777	October 1995	Kitajima et al.
5460968	October 1995	Yoshida et al.
5482473	January 1996	Lord et al.
5506200	April 1996	Hirschkoff et al.
5507288	April 1996	Bocker et al.
5508200	April 1996	Tiffany et al.
5510266	April 1996	Bonner et al.
5514152	May 1996	Smith
5527892	June 1996	Borsotti et al.
5568806	October 1996	Cheney, II et al.
5569287	October 1996	Tezuka et al.
5575403	November 1996	Charlton et al.
5577499	November 1996	Teves
5582184	December 1996	Erickson et al.
5586553	December 1996	Halili et al.
5591139	January 1997	Lin et al.
5611809	March 1997	Marshall et al.
5624458	April 1997	Lipscher
5630986	May 1997	Charlton et al.
5632410	May 1997	Moulton et al.
5636632	June 1997	Bommannan et al.
5647851	July 1997	Pokras
5658515	August 1997	Lee et al.
5660791	August 1997	Brenneman et al.
5676850	October 1997	Reed et al.
5680858	October 1997	Hansen et al.
5681484	October 1997	Zanzucchi et al.
5682233	October 1997	Brinda
5697901	December 1997	Eriksson
5701181	December 1997	Boiarski et al.
5701910	December 1997	Powles et al.
5705018	January 1998	Hartley
5708787	January 1998	Nakano et al.
5715417	February 1998	Gardien et al.
5730753	March 1998	Morita
5735273	April 1998	Kurnik et al.
5736103	April 1998	Pugh
5741211	April 1998	Renirie et al.
5746217	May 1998	Erickson et al.
5746720	May 1998	Stouder, Jr.
5757666	May 1998	Schreiber et al.
5759364	June 1998	Charlton et al.
5766066	June 1998	Ranniger
5771890	June 1998	Tamada
5797693	August 1998	Jaeger
5801057	September 1998	Smart et al.
5807375	September 1998	Gross et al.
5820570	October 1998	Erickson et al.
5827183	October 1998	Kurnik et al.
5840020	November 1998	Heinonen et al.
5841126	November 1998	Fossum et al.
5843692	December 1998	Phillips et al.
5846837	December 1998	Thym et al.
5854074	December 1998	Charlton et al.
D403975	January 1999	Douglas et al.
5855801	January 1999	Lin et al.
5856195	January 1999	Charlton et al.
5858194	January 1999	Bell
5866281	February 1999	Guckel et al.
5871494	February 1999	Simons et al.
5879310	March 1999	Sopp et al.
5879326	March 1999	Godshall et al.
5879367	March 1999	Latterell et al.
5891053	April 1999	Sesekura
5893870	April 1999	Talen et al.
5911711	June 1999	Pelkey
5911737	June 1999	Lee et al.
5912139	June 1999	Iwata et al.
5925021	July 1999	Castellano et al.
5928207	July 1999	Pisano et al.
5930873	August 1999	Wyser
5938679	August 1999	Freeman et al.
5945678	August 1999	Yanagisawa
5951492	September 1999	Douglas et al.
5951493	September 1999	Douglas et al.
5954685	September 1999	Tierney
5962215	October 1999	Douglas et al.
5968760	October 1999	Phillips et al.
5968765	October 1999	Grage et al.
5971941	October 1999	Simons et al.
5972294	October 1999	Smith et al.
5986754	November 1999	Harding
5989409	November 1999	Kurnik et al.
5993189	November 1999	Mueller et al.
6001067	December 1999	Shults et al.
6005545	December 1999	Nishida et al.
6010463	January 2000	Lauks et al.
6010519	January 2000	Mawhirt et al.
6014135	January 2000	Fernandes
6014577	January 2000	Henning et al.
6023629	February 2000	Tamada
6027459	February 2000	Shain et al.
6030827	February 2000	Davis et al.
6032059	February 2000	Henning et al.
6036924	March 2000	Simons et al.
6041253	March 2000	Kost et al.
6050988	April 2000	Zuck
6056701	May 2000	Duchon et al.
6056734	May 2000	Jacobsen et al.
6058321	May 2000	Swayze et al.
6059815	May 2000	Lee et al.
6061128	May 2000	Zweig et al.
6063039	May 2000	Cunningham et al.
6071294	June 2000	Simons et al.
6077660	June 2000	Wong et al.
6080116	June 2000	Erickson et al.
6083196	July 2000	Trautman et al.
6086544	July 2000	Hibner et al.
6090790	July 2000	Eriksson
6091975	July 2000	Daddona et al.
6093156	July 2000	Cunningham et al.
6097831	August 2000	Wieck et al.
6099484	August 2000	Douglas et al.
6100107	August 2000	Lei et al.
6102933	August 2000	Lee et al.
6103033	August 2000	Say et al.
6103197	August 2000	Werner
6106751	August 2000	Talbot et al.
6118126	September 2000	Zanzucchi
6120676	September 2000	Heller et al.
6123861	September 2000	Santini, Jr. et al.
6126899	October 2000	Woudenberg et al.
6132449	October 2000	Lum et al.
6139562	October 2000	Mauze et al.
6142939	November 2000	Eppstein et al.
6152942	November 2000	Brenneman et al.
6162639	December 2000	Douglas
6175752	January 2001	Say et al.
6176865	January 2001	Mauze et al.
6183434	February 2001	Eppstein et al.
6183489	February 2001	Douglas et al.
6187210	February 2001	Lebouiz et al.
6192891	February 2001	Gravel et al.
6200296	March 2001	Dibiasi et al.
6206841	March 2001	Cunningham et al.
6214626	April 2001	Meller et al.
6219574	April 2001	Cormier et al.
6228100	May 2001	Schraga
6230051	May 2001	Cormier et al.
6231531	May 2001	Lum et al.
6241862	June 2001	McAleer et al.
6242207	June 2001	Douglas et al.
6245215	June 2001	Douglas et al.
6251083	June 2001	Yum et al.
6251260	June 2001	Heller et al.
6254586	July 2001	Mann et al.
6255061	July 2001	Mori et al.
6256533	July 2001	Yuzhakov et al.
6268162	July 2001	Phillips et al.
6271045	August 2001	Douglas et al.
6272364	August 2001	Kurnik
6283926	September 2001	Cunningham et al.
6289230	September 2001	Chaiken et al.
6298254	October 2001	Tamada
6299578	October 2001	Kurnik et al.
6309351	October 2001	Kurnik et al.
D450711	November 2001	Istvan et al.
6312612	November 2001	Sherman et al.
6312888	November 2001	Wong et al.
6322808	November 2001	Trautman et al.
6329161	December 2001	Heller et al.
6331266	December 2001	Powell et al.
6332871	December 2001	Douglas et al.
6334856	January 2002	Allen et al.
6350273	February 2002	Minagawa et al.
6352514	March 2002	Douglas et al.
6356776	March 2002	Berner et al.
6358265	March 2002	Thorne, Jr. et al.
6364890	April 2002	Lum et al.
6375626	April 2002	Allen et al.
6375627	April 2002	Mauze et al.
6379969	April 2002	Mauze et al.
6391005	May 2002	Lum et al.
6409679	June 2002	Pyo
6428664	August 2002	BhulLar et al.
6449608	September 2002	Morita et al.
6455324	September 2002	Douglas
6500134	December 2002	Cassone
6520973	February 2003	McGarry
6530892	March 2003	Kelly
6537243	March 2003	Henning et al.
6540675	April 2003	Aceti et al.
6544475	April 2003	Douglas et al.
6555061	April 2003	Leong et al.
6558624	May 2003	Lemmon et al.
6579690	June 2003	Bonnecaze et al.
6602205	August 2003	Erickson et al.
6612111	September 2003	Hodges et al.
6616616	September 2003	Fritz et al.
6626874	September 2003	Duchamp
6656167	December 2003	Numao et al.
6679852	January 2004	Schmelzeisen-Redeker et al.
6706000	March 2004	Perez et al.
6706049	March 2004	Moerman
6706159	March 2004	Moerman et al.
6740800	May 2004	Cunningham
6743635	June 2004	Neel et al.
6748275	June 2004	Lattner et al.
6753187	June 2004	Cizdziel et al.
6766817	July 2004	da Silva
6793633	September 2004	Douglas et al.
6830669	December 2004	Miyazaki et al.
6836678	December 2004	Tu
6837858	January 2005	Cunningham et al.
6847451	January 2005	Pugh
6918404	July 2005	Da Silva
6919960	July 2005	Hansen et al.
6923764	August 2005	Aceti et al.
6936476	August 2005	Anderson et al.
6988996	January 2006	Roe et al.
7004928	February 2006	Aceti et al.
7011630	March 2006	Desai et al.
7025774	April 2006	Freeman et al.
7052652	May 2006	Zanzucchi et al.
7066586	June 2006	Da Silva
7066890	June 2006	Lam et al.
7141058	November 2006	Briggs et al.
7156809	January 2007	Quy
7192061	March 2007	Martin
D540343	April 2007	Cummins et al.
7223365	May 2007	Von Der Goltz
7225008	May 2007	Ward et al.
7226461	June 2007	Boecker et al.
D551243	September 2007	Young
7270970	September 2007	Anderson et al.
7297151	November 2007	Boecker et al.
7343188	March 2008	Sohrab
7344507	March 2008	Briggs et al.
7379167	May 2008	Mawhirt et al.
7427377	September 2008	Zanzucchi et al.
D599373	September 2009	Kobayashi et al.
D601257	September 2009	Berlinger et al.
7585278	September 2009	Aceti et al.
D601444	October 2009	Jones et al.
D601578	October 2009	Poulet et al.
7682318	March 2010	Alden et al.
D622393	August 2010	Gatrall et al.
7803123	September 2010	Perez et al.
7887494	February 2011	Emery et al.
D642191	July 2011	Barnett et al.
8012103	September 2011	Escutia et al.
8012104	September 2011	Escutia et al.
8105849	January 2012	McDevitt et al.
D654926	February 2012	Lipman et al.
8231832	July 2012	Zanzucchi et al.
8303518	November 2012	Aceti et al.
8360993	January 2013	Escutia et al.
8360994	January 2013	Escutia et al.
8372015	February 2013	Escutia et al.
8382681	February 2013	Escutia et al.
D691174	October 2013	Lipman et al.
8795201	August 2014	Escutia et al.
8801631	August 2014	Escutia et al.
8919605	December 2014	Lipman et al.
8969097	March 2015	Emery et al.
9060723	June 2015	Escutia et al.
9095292	August 2015	Zanzucchi et al.
9366636	June 2016	Emery et al.
9380974	July 2016	Litherland et al.
2001/0001034	May 2001	Douglas
2001/0027328	October 2001	Lum et al.
2001/0053891	December 2001	Ackley
2002/0002326	January 2002	Causey, III et al.
2002/0002344	January 2002	Douglas et al.
2002/0004640	January 2002	Conn et al.
2002/0006355	January 2002	Whitson
2002/0016568	February 2002	Lebel et al.
2002/0020688	February 2002	Sherman et al.
2002/0023852	February 2002	Mcivor et al.
2002/0042594	April 2002	Lum et al.
2002/0052618	May 2002	Haar et al.
2002/0087056	July 2002	Aceti et al.
2002/0136667	September 2002	Subramanian et al.
2002/0137998	September 2002	Smart et al.
2002/0160520	October 2002	Orloff et al.
2002/0168290	November 2002	Yuzhakov et al.
2002/0169394	November 2002	Eppstein et al.
2002/0169411	November 2002	Sherman et al.
2002/0177761	November 2002	Orloff et al.
2002/0183102	December 2002	Withers et al.
2002/0188223	December 2002	Perez et al.
2002/0198444	December 2002	Uchigaki et al.
2003/0012693	January 2003	Otillar et al.
2003/0028087	February 2003	Yuzhakov et al.
2003/0028125	February 2003	Yuzhakov et al.
2003/0039587	February 2003	Niermann
2003/0083685	May 2003	Freeman et al.
2003/0083686	May 2003	Freeman et al.
2003/0105961	June 2003	Zatloukal et al.
2003/0116596	June 2003	Terasawa
2003/0135166	July 2003	Gonnelli
2003/0135333	July 2003	Aceti
2003/0153844	August 2003	Smith et al.
2003/0153900	August 2003	Aceti et al.
2003/0175987	September 2003	Verdonk et al.
2003/0206302	November 2003	Pugh
2003/0207441	November 2003	Eyster et al.
2003/0208113	November 2003	Mault et al.
2003/0211619	November 2003	Olson et al.
2003/0212344	November 2003	Yuzhakov et al.
2003/0212347	November 2003	Sohrab
2003/0216628	November 2003	Bortz et al.
2004/0010207	January 2004	Flaherty et al.
2004/0030353	February 2004	Schmelzeisen-redeker et al.
2004/0049219	March 2004	Briggs et al.
2004/0059256	March 2004	Perez
2004/0073140	April 2004	Douglas
2004/0092842	May 2004	Boecker et al.
2004/0092995	May 2004	Boecker et al.
2004/0094432	May 2004	Neel et al.
2004/0096959	May 2004	Stiene et al.
2004/0098009	May 2004	Boecker et al.
2004/0102803	May 2004	Boecker et al.
2004/0122339	June 2004	Roe
2004/0132167	July 2004	Rule et al.
2004/0138588	July 2004	Saikley et al.
2004/0155084	August 2004	Brown
2004/0157339	August 2004	Burke et al.
2004/0178218	September 2004	Schomakers et al.
2004/0186394	September 2004	Roe et al.
2004/0191119	September 2004	Zanzucchi et al.
2004/0202576	October 2004	Aceti et al.
2004/0236251	November 2004	Roe et al.
2004/0238675	December 2004	Banaszkiewicz et al.
2004/0259180	December 2004	Burke et al.
2005/0010134	January 2005	Douglas et al.
2005/0015020	January 2005	LeVaughn et al.
2005/0027182	February 2005	Siddiqui et al.
2005/0038680	February 2005	McMahon
2005/0070819	March 2005	Poux et al.
2005/0096686	May 2005	Allen
2005/0106713	May 2005	Phan et al.
2005/0159678	July 2005	Taniike et al.
2005/0187532	August 2005	Thurau et al.
2005/0192492	September 2005	Cho et al.
2005/0202567	September 2005	Zanzucchi et al.
2005/0202733	September 2005	Yoshimura et al.
2005/0215872	September 2005	Berner et al.
2005/0215923	September 2005	Wiegel
2005/0245844	November 2005	Mace et al.
2005/0277972	December 2005	Wong et al.
2006/0008389	January 2006	Sacherer et al.
2006/0036134	February 2006	Tarassenko et al.
2006/0117616	June 2006	Jones et al.
2006/0122536	June 2006	Haar et al.
2006/0135873	June 2006	Karo et al.
2006/0155317	July 2006	List
2006/0178600	August 2006	Kennedy et al.
2006/0189908	August 2006	Kennedy
2006/0204399	September 2006	Freeman et al.
2006/0229533	October 2006	Hoenes et al.
2006/0241517	October 2006	Fowler et al.
2006/0257993	November 2006	Mcdevitt et al.
2006/0259102	November 2006	Slatkine
2006/0281187	December 2006	Emery et al.
2007/0016104	January 2007	Jansen et al.
2007/0017824	January 2007	Rippeth et al.
2007/0033074	February 2007	Nitzan et al.
2007/0078313	April 2007	Emery et al.
2007/0078358	April 2007	Escutia et al.
2007/0083130	April 2007	Thomson et al.
2007/0083131	April 2007	Escutia et al.
2007/0093786	April 2007	Goldsmith et al.
2007/0179404	August 2007	Escutia et al.
2007/0179405	August 2007	Emery et al.
2007/0253531	November 2007	Okuzawa et al.
2007/0255181	November 2007	Alvarez-icaza et al.
2007/0255302	November 2007	Koeppel et al.
2008/0012701	January 2008	Kass et al.
2008/0046831	February 2008	Imai et al.
2008/0077048	March 2008	Escutia et al.
2008/0139910	June 2008	Mastrototaro et al.
2008/0194934	August 2008	Ray et al.
2008/0268485	October 2008	Guarino et al.
2009/0149717	June 2009	Brauer et al.
2009/0156923	June 2009	Power et al.
2010/0010374	January 2010	Escutia et al.
2010/0021948	January 2010	Lipman et al.
2010/0095229	April 2010	Dixon et al.
2010/0185120	July 2010	Sacherer et al.
2010/0217155	August 2010	Poux et al.
2010/0331650	December 2010	Batman et al.
2011/0098599	April 2011	Emery et al.
2011/0201909	August 2011	Emery et al.
2011/0294152	December 2011	Lipman et al.
2012/0166090	June 2012	Lipman et al.
2012/0296179	November 2012	Zanzucchi et al.
2013/0110516	May 2013	Abulhaj et al.
2013/0158430	June 2013	Aceti et al.
2013/0158432	June 2013	Escutia et al.
2013/0172698	July 2013	Reynolds et al.
2013/0274568	October 2013	Escutia et al.
2014/0316301	October 2014	Escutia et al.
2014/0336480	November 2014	Escutia et al.
2014/0376762	December 2014	Lipman et al.
2015/0153351	June 2015	Lipman et al.
2016/0038066	February 2016	Escutia et al.

Foreign Patent Documents


2 513 465	Aug 2004	CA
199 22 413	Nov 2000	DE
103 02-501	Aug 2004	DE
0 256 806	Feb 1988	EP
0 396-016	Nov 1990	EP
0 396-016	Nov 1990	EP
0 255-338	Feb 1998	EP
1 266-607	Dec 2002	EP
1 266-607	Dec 2002	EP
1 369 688	Oct 2003	EP
1 360-934	Nov 2003	EP
1 360-934	Nov 2003	EP
1 486-766	Dec 2004	EP
1 486-766	Dec 2004	EP
1 529-489	May 2005	EP
1 529-489	May 2005	EP
1 769-735	Apr 2007	EP
1 987 766	Nov 2008	EP
63-305841	Dec 1988	JP
3-63570	Mar 1991	JP
03093189	Apr 1991	JP
7-67861	Mar 1995	JP
7-213925	Aug 1995	JP
9-168530	Jun 1997	JP
9-313465	Sep 1997	JP
9-266889	Oct 1997	JP
9-294737	Nov 1997	JP
10-024028	Jan 1998	JP
10-318970	Dec 1998	JP
11056822	Mar 1999	JP
11281779	Oct 1999	JP
2000-116629	Apr 2000	JP
2000-126161	May 2000	JP
2000-168754	Jun 2000	JP
2000-254111	Sep 2000	JP
2001-159618	Jun 2001	JP
2001-515203	Sep 2001	JP
2001-305096	Oct 2001	JP
2001-330581	Nov 2001	JP
2002-502045	Jan 2002	JP
2002-085384	Mar 2002	JP
2002-514453	May 2002	JP
2002-168862	Jun 2002	JP
2003-507719	Feb 2003	JP
2003-108679	Apr 2003	JP
2003-180417	Jul 2003	JP
2004-000598	Jan 2004	JP
2004-500948	Jan 2004	JP
2004-117339	Apr 2004	JP
2004-209266	Jul 2004	JP
2004-519302	Jul 2004	JP
2004-522500	Jul 2004	JP
2004-528936	Sep 2004	JP
2005-503538	Feb 2005	JP
2005-087613	Apr 2005	JP
2006-512969	Apr 2005	JP
2005-525149	Aug 2005	JP
2005-237938	Sep 2005	JP
2005-525846	Sep 2005	JP
2005-527254	Sep 2005	JP
2006-512974	Apr 2006	JP
2006-516723	Jul 2006	JP
2006-521555	Sep 2006	JP
2006-527013	Nov 2006	JP
2007-054407	Mar 2007	JP
2007-067698	Mar 2007	JP
2007-521031	Aug 2007	JP
2007-311196	Nov 2007	JP
2008-125813	Jun 2008	JP
WO-91/14212	Sep 1991	WO
WO-94/13203	Jun 1994	WO
WO-95/10223	Apr 1995	WO
WO-95/10223	Apr 1995	WO
WO-96/04857	Feb 1996	WO
WO-96/07907	Mar 1996	WO
WO-96/14026	May 1996	WO
WO-96/25088	Aug 1996	WO
WO-97/15227	May 1997	WO
WO-97/29847	Aug 1997	WO
WO-97/30344	Aug 1997	WO
WO-97/41421	Nov 1997	WO
WO-98/31275	Jul 1998	WO
WO-98/35225	Aug 1998	WO
WO-99/12008	Mar 1999	WO
WO-99/44508	Sep 1999	WO
WO-99/58051	Nov 1999	WO
WO-00/09184	Feb 2000	WO
WO-00/13573	Mar 2000	WO
WO-00/14269	Mar 2000	WO
WO-00/14535	Mar 2000	WO
WO-00/18449	Apr 2000	WO
WO-00/18449	Apr 2000	WO
WO-00/36400	Jun 2000	WO
WO-00/42422	Jul 2000	WO
WO-00/74763	Dec 2000	WO
WO-00/74763	Dec 2000	WO
WO-00/78208	Dec 2000	WO
WO-01/13795	Mar 2001	WO
WO-01/16575	Mar 2001	WO
WO-01/52727	Jul 2001	WO
WO-01/64105	Sep 2001	WO
WO-01/64105	Sep 2001	WO
WO-01/72220	Oct 2001	WO
WO-01/80728	Nov 2001	WO
WO-01/85233	Nov 2001	WO
WO-01/85233	Nov 2001	WO
WO-01/91634	Dec 2001	WO
WO-01/91634	Dec 2001	WO
WO-02/00101	Jan 2002	WO
WO-02/00101	Jan 2002	WO
WO-02/49507	Jun 2002	WO
WO-02/49509	Jun 2002	WO
WO-02/49509	Jun 2002	WO
WO-02/078533	Oct 2002	WO
WO-02/078533	Oct 2002	WO
WO-02/082052	Oct 2002	WO
WO-02/082052	Oct 2002	WO
WO-02/093144	Nov 2002	WO
WO-02/100251	Dec 2002	WO
WO-02/100251	Dec 2002	WO
WO-02/101359	Dec 2002	WO
WO-02/101359	Dec 2002	WO
WO-03/007819	Jan 2003	WO
WO-03/030984	Apr 2003	WO
WO-03/066128	Aug 2003	WO
WO-03/066128	Aug 2003	WO
WO-03/070099	Aug 2003	WO
WO-03/071940	Sep 2003	WO
WO-03/071940	Sep 2003	WO
WO-2004/062499	Jul 2004	WO
WO-2004/062500	Jul 2004	WO
WO-2004/062500	Jul 2004	WO
WO-2004/064636	Aug 2004	WO
WO-2004/085995	Oct 2004	WO
WO-2004/085995	Oct 2004	WO
WO-2004/091693	Oct 2004	WO
WO-2004/091693	Oct 2004	WO
WO-2005/006939	Jan 2005	WO
WO-2005/006939	Jan 2005	WO
WO-2005/009238	Feb 2005	WO
WO-2005/018709	Mar 2005	WO
WO-2005/018709	Mar 2005	WO
WO-2005/084546	Sep 2005	WO
WO-2005/084546	Sep 2005	WO
WO-2005/085995	Sep 2005	WO
WO-2006/138226	Dec 2006	WO
WO-2006/138226	Dec 2006	WO
WO-2007/041062	Apr 2007	WO
WO-2007/041062	Apr 2007	WO
WO-2007/041063	Apr 2007	WO
WO-2007/041063	Apr 2007	WO
WO-2007/041244	Apr 2007	WO
WO-2007/041244	Apr 2007	WO
WO-2007/041287	Apr 2007	WO
WO-2007/041287	Apr 2007	WO
WO-2007/041355	Apr 2007	WO
WO-2007/041355	Apr 2007	WO
WO2007/131036	May 2007	WO
WO-2007/108519	Sep 2007	WO
WO-2007/112034	Oct 2007	WO
WO-2007/112034	Oct 2007	WO
WO-2008/027319	Mar 2008	WO
WO-2008/027319	Mar 2008	WO
WO-2008/062648	May 2008	WO
WO-2009/145920	Dec 2009	WO
WO-2009/148624	Dec 2009	WO
WO-2009/148626	Dec 2009	WO
WO-2011/065981	Jun 2011	WO
WO-2011/162823	Dec 2011	WO
WO-2013/020103	Feb 2013	WO
WO-2014/205412	Dec 2014	WO

Other References

Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority Forms (PCT/ISA/220, PCT/ISA/210 and PCT/ISA/237) issued in corresponding International Application No. PCT/US 09/03441 dated Jul. 28, 2009. cited by applicant .
ADA Consensus Development Panel. (Jan.-Feb. 1987). "Consensus Statement on Self-Monitoring of Blood Glucose," Diabetes Care 10(1):95-99. cited by applicant .
ADA (Jan. 1994). "Self-Monitoring of Blood Glucose," Consensus Statement Diabetes Care 17(1):81-86. cited by applicant .
Anonymous. (Sep. 30, 1993). "The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus." The New England Journal of Medicine 329(14):977-986. cited by applicant .
Anonymous. (Jun. 23, 1998). Taking the "Ouch" Out of Needles: Arrays of "Microneedles" Offer New Techniques for Drug Delivery, Science Daily, located at <http:www.sciencedaily.com/releases/1998/06/980623045850.htm>, last visited Jan. 14, 2014, 3 pages. cited by applicant .
Beregszaszi, M. et al. (Jul. 1997). "Nocturnal Hypoglycemia in Children and Adolescents with Insulin-Dependent Diabetes Mellitus: Prevalence and Risk Factors," J. Pediatrics 131(1 Pt. 1):27-33. cited by applicant .
Chase, H.P. et al. (Feb. 2001). "Continuous Subcutaneous Glucose Monitoring in Children with Type 1 Diabetes," Pediatrics 107(2):222-226. cited by applicant .
Clarke, W.L. et al. (Sep.-Oct. 1987). "Evaluating Clinical Accuracy of Systems for Self-Monitoring of Blood Glucose," Diabetes Care 10(5):622-628. cited by applicant .
Collison, M.E. et al. (Sep. 1999). "Analytical Characterization of Electrochemical Biosensor Test Strips for Measurement of Glucose in Low-Volume Interstitial Fluid Samples," Clinical Chemistry 45(9):1665-1673. cited by applicant .
Coster, S. et al. (2000). "Monitoring Blood Glucose Control in Diabetes Mellitus: A Systematic Review." Health Technology Assessment 4(12):1-93. cited by applicant .
Cox, D.J. et al. (Jun. 1997). "Understanding Error Grid Analysis," Diabetes Care 20(6):911-912. cited by applicant .
D'Arrigo, T.D. (Mar. 2000). "GlucoWatch Monitor Poised for Approval," Diabetes Forecast, 53(3):43-44. cited by applicant .
Feldman, B. et al. (2000). "FreeStyle.TM.: A Small-Volume Electrochemical Glucose Sensor for Home Blood Glucose Testing," Diabetes Technology and Therapeutics, 2(2):221-229. cited by applicant .
Johnson, R.N. et al. (Jan. 1998). "Accuracy of Devices Used for Self-Monitoring of Blood Glucose," Annals of Clinical Biochemistry 35(1):68-74. cited by applicant .
Johnson, R.N. et al. (Jan. 1999). "Analytical Error of Home Glucose Monitors: A Comparison of 18 Systems," Annals of Clinical Biochemistry 36(1):72-79. cited by applicant .
Johnson, R.N. et al. (2001). "Error Detection and Measurement in Glucose Monitors," Clinica Chimica Acta 307:61-67. cited by applicant .
Kumetrix, Inc. (Dec. 1999). "Painless Blood Glucose Monitoring, Courtesy of the Mosquito," Start-Up pp. 27-28. cited by applicant .
Lee, S-C. (Jun. 1999). "Light Scattering by Closely Spaced Parallel Cylinders Embedded in a Finite Dielectric Slab," Journal of the Optical Society of America A 16(6):1350-1361. cited by applicant .
McGarraugh, G. et al. (2001). "Physiological Influences on Off-Finger Glucose Testing," Diabetes Technology & Therapeutics 3(3):367-376. cited by applicant .
McNichols, R.J. et al. (Jan. 2000). "Optical Glucose Sensing in Biological Fluids: An Overview," Journal of Biomedical Optics, 5(1):5-16. cited by applicant .
Mahler, R.J. et al. (1999). "Clinical Review 102, Type 2 Diabetes Melitus: Update on Diagnosis Pathophysiology, and Treatment," The Journal of Clinical Endocrinology and Metabolism 84(4):1165-1171. cited by applicant .
Medline Plus. (Jun. 17, 2008). , Medical Encyclopedia, Monitor Blood Glucose-Series: Part 1-4, 6 pages. cited by applicant .
Neeley, W.E. et al. (1981). "An Instrument for Digital Matrix Photometry," Clinical Chemistry 27(10):1665-1668. cited by applicant .
Neeley, W.E. (1983). "Reflectance Digital Matrix Photometry," Clinical Chemistry 29(6):1038-1041. cited by applicant .
Neeley, W.E. (1983). "Multilayer Film Analysis for Glucose in 1-.mu.L Samples of Plasma," Clinical Chemistry 29(12):2103-2105. cited by applicant .
Neeley, W.E. (1988). "A Reflectance Photometer with a Square Photodiode Array Detector for Use on Multilayer Dry-Film Slides," Clinical Chemistry 34(11):2367-2370. cited by applicant .
Otto, E. et al. (2000). "An Intelligent Diabetes Software Prototype: Predicting Blood Glucose Levels and Recommending Regimen Changes," Diabetes Technology and Therapeutics 2(4):569-576. cited by applicant .
Pfohl, M. et al. (2000). "Spot Glucose Measurement in Epidermal Interstitial Fluid--An Alternative to Capillary Blood Glucose Estimation," Experimental and Clinical Endocrinology & Diabetes 108(1):1-4. cited by applicant .
Princen, H.M. (May 1969). "Capillary Phenomena in Assemblies of Parallel Cylinders, I. Capillary Rise Between Two Cylinders," Journal of Colloid and Interface Science 30(1):69-75. cited by applicant .
Princen, H.M. (Jul. 1969). "Capillary Phenomena in Assemblies of Parallel Cylinders, II. Capillary Rise in Systems with More Than Two Cylinders," Journal of Colloid and Interface Science 30(3):359-371. cited by applicant .
Rebrin, K. et al. (Sep. 1999). "Subcutaneous Glucose Predicts Plasma Glucose Independent of Insulin: Implications for Continuous Monitoring," American Journal of Physiology 277(3):E561-E571. cited by applicant .
Rosen, S. (1999). "Road to New-Age Glucose Monitoring Still Rocky," Diagnostic Insight, pp. 4-5, 12-13, 16. cited by applicant .
Smart, W.H. et al. (2000). "The Use of Silicon Microfabrication Technology in Painless Glucose Monitoring," Diabetes Technology & Therapeutics 2(4):549-559. cited by applicant .
Svedman, C. et al. (Apr. 1999). "Skin Mini-Erosion Technique for Monitoring Metabolites in Interstitial Fluid: Its Feasibility Demonstrated by OGTT Results in Diabetic and Non-Diabetic Subjects," Scand. J. Clin. Lab. Invest. 59(2):115-123. cited by applicant .
Trinder, P. (1969). "Determination of Glucose in Blood Using Glucose Oxidase with an Alternate Oxygen Acceptor," Annals of Clinical Biochemistry 6:24-28. cited by applicant .
Yum, S. I. et al. (Nov. 1, 1999). "Capillary Blood Sampling for Self-Monitoring of Blood Glucose," Diabetes Technology & Therapeutics, 1(1):29-37. cited by applicant .
Extended European Search Report mailed on Jun. 16, 2014, for EP Application No. 09758787.7, filed on Jun. 8, 2009, 6 pages. cited by applicant .
Clarke, W.L. et al. (1981). "Evaluation of a New Reflectance Photometer for Use in Home Blood Glucose Monitoring," Diabetes Care 4(5):547-550. cited by applicant .
Extended European Search Report mailed on Jul. 18, 2013, for EP Application No. 06 772 943.4, filed on Jun. 13, 2006, 7 pages. cited by applicant .
Extended European Search Report mailed on Aug. 27, 2012, for European Patent Application No. 09 758 789.3, filed on Jun. 8, 2009, 13 pages. cited by applicant .
Extended European Search Report mailed on Oct. 27, 2016, for EP Application No. 11 798 518.4, filed on Jun. 24, 2011, 7 pages. cited by applicant .
Final Office Action mailed on May 5, 2016, for U.S. Appl. No. 14/311,114, filed Jun. 20, 2014, 13 pages. cited by applicant .
Final Office Action mailed on Oct. 15, 2009, for U.S. Appl. No. 11/239,122, filed Sep. 30, 2005, 13 pages. cited by applicant .
Final Office Action mailed on Aug. 14, 2012, for U.S. Appl. No. 13/037,089, filed Feb. 28, 2011, 14 pages. cited by applicant .
Final Office Action mailed on Sep. 23, 2013, for U.S. Appl. No. 13/037,089, filed Feb. 28, 2011, 14 pages. cited by applicant .
Final Office Action mailed on Mar. 27, 2014, for U.S. Appl. No. 12/457,332, filed Jun. 8, 2009, 11 pages. cited by applicant .
Final Office Action mailed on Jan. 20, 2016, for U.S. Appl. No. 12/457,332, filed Jun. 8, 2009, 10 pages. cited by applicant .
Final Office Action mailed on Apr. 30, 2013, for U.S. Appl. No. 13/168,644, filed Jun. 24, 2011, 10 pages. cited by applicant .
Final Office Action mailed on Sep. 30, 2015, for U.S. Appl. No. 13/168,644, filed Jun. 24, 2011, 16 pages. cited by applicant .
Final Office Action mailed on Aug. 12, 2016, for U.S. Appl. No. 13/168,644, filed Jun. 24, 2011, 18 pages. cited by applicant .
International Search Report mailed on Oct. 15, 2014 for PCT Application No. PCT/US2014/043516, filed on Jun. 20, 2014, 2 pages. cited by applicant .
International Search Report mailed on Jan. 16, 2008, for PCT Application No. PCT/US2006/022840, filed on Jun. 13, 2006, 1 page. cited by applicant .
International Search Report mailed on Nov. 14, 2011, for PCT Application No. PCT/US2011/001132, filed on Jun. 24, 2011, 2 pages. cited by applicant .
International Search Report mailed on Jul. 28, 2009, for PCT Application No. PCT/US2009/03445, filed on Jun. 8, 2009, 2 pages. cited by applicant .
Non-Final Office Action mailed on Mar. 19, 2009, for U.S. Appl. No. 11/239,122, filed Sep. 30, 2005, 15 pages. cited by applicant .
Non-Final Office Action mailed on Sep. 1, 2010, for U.S. Appl. No. 11/239,122, filed Sep. 30, 2005, 15 pages. cited by applicant .
Non-Final Office Action mailed on Aug. 19, 2015, for U.S. Appl. No. 14/311,114, filed Jun. 20, 2014, 15 pages. cited by applicant .
Non-Final Office Action mailed on Sep. 13, 2011, for U.S. Appl. No. 13/037,089, filed Feb. 28, 2011, 14 pages. cited by applicant .
Non-Final Office Action mailed on Feb. 28, 2013, for U.S. Appl. No. 13/037,089, filed Feb. 28, 2011, 12 pages. cited by applicant .
Non-Final Office Action mailed on Apr. 10, 2014, for U.S. Appl. No. 13/037,089, filed Feb. 28, 2011, 14 pages. cited by applicant .
Non-Final Office Action mailed on May 29, 2015, for U.S. Appl. No. 14/614,177, filed Feb. 4, 2015, 13 pages. cited by applicant .
Non-Final Office Action mailed on Mar. 2, 2012, for U.S. Appl. No. 12/457,332, filed Jun. 8, 2009, 7 pages. cited by applicant .
Non-Final Office Action mailed on May 30, 2013, for U.S. Appl. No. 12/457,332, filed Jun. 8, 2009, 7 pages. cited by applicant .
Non-Final Office Action mailed on Jun. 22, 2012, for U.S. Appl. No. 13/168,644, filed Jun. 24, 2011, 8 pages. cited by applicant .
Non-Final Office Action mailed on Jan. 13, 2015, for U.S. Appl. No. 13/168,644, filed Jun. 24, 2011, 12 pages. cited by applicant .
Non-Final Office Action mailed on Jun. 25, 2015, for U.S. Appl. No. 12/457,332, filed Jun. 8, 2009, 7 pages. cited by applicant .
Notice of Allowance mailed on Sep. 18, 2014, for U.S. Appl. No. 13/037,089, filed Feb. 28, 2011, 9 pages. cited by applicant .
Notice of Allowance mailed on Feb. 16, 2016, for U.S. Appl. No. 14/614,177, filed Feb. 4, 2015, 7 pages. cited by applicant .
Restriction Requirement mailed on Sep. 29, 2011, for U.S. Appl. No. 12/457,332, filed Jun. 8, 2009, 6 pages. cited by applicant .
Restriction Requirement mailed on Dec. 22, 2011, for U.S. Appl. No. 12/457,332, filed Jun. 8, 2009, 6 pages. cited by applicant .
Tietz, N.W. (1986).Textbook of Clinical Chemistry, W. B. Saunders Company, pp. 1533 and 1556. cited by applicant .
Written Opinion mailed on Nov. 14, 2011, for PCT Application No. PCT/US2011/001132, filed on Jun. 24, 2011, 6 pages. cited by applicant .
Written Opinion of the International Searching Authority mailed on Oct. 15, 2014 for PCT Application No. PCT/US2014/043516, filed on Jun. 20, 2014, 5 pages. cited by applicant .
Written Opinion of the International Searching Authority mailed on Jan. 16, 2008, for PCT Application No. PCT/US2006/022840, filed on Jun. 13, 2006, 3 pages. cited by applicant .
Written Opinion of the International Searching Authority mailed on Jul. 28, 2009, for PCT Application No. PCT/US2009/03445, filed on Jun. 8, 2009, 4 pages. cited by applicant.

Primary Examiner: Siefke; Sam P

Parent Case Text

CROSS-REFERENCE TO RELATED APPLICATIONS

The present application claims priority to U.S. patent application No. 61/129,149, filed Jun. 6, 2008.

Claims

We claim:

1. A device for performing an assay to determine the presence or concentration of an analyte contained in a sample of body fluid, the device comprising: at least a first analyte quantification member; at least one passageway in fluid communication with the first analyte quantification member; a sensor configured to interrogate at least the first analyte quantification member and to detect the presence or absence of an adequate sample volume; a vacuum source configured to assist in the expression of body fluid from a wound; a non-transitory memory device programmed with instructions to: activate the vacuum source; initiate a first time period and interrogate the first analyte quantification member using the sensor to detect the presence or absence of an adequate sample volume applied to the first analyte quantification member within the first time period; and upon the detection of the absence of an adequate sample volume, initiate a second time period and signal a user to manually milk the wound and introduce an additional sample of body fluid into the at least one passageway to increase the sample volume applied to the first analyte quantification member; and a processor programmed to carry out the instructions on the non-transitory memory device.

2. The device of claim 1, wherein the non-transitory memory device further comprises programmed instructions to interrogate the first analyte quantification member using the sensor during the second time period to detect the presence or absence of an adequate sample volume.

3. The device of claim 2, wherein the non-transitory memory device further comprises programmed instructions to signal the user that the assay is being terminated upon detection of the absence of an adequate sample volume within the second time period.

4. The device of claim 2, wherein the non-transitory memory device further comprises programmed instructions to continue with the assay upon detection of an adequate sample volume during the second time period.

5. The device of claim 4, wherein the non-transitory memory device further comprises programmed instructions to interrogate the first analyte quantification member using the sensor subsequent to the second time period to ascertain the presence or concentration of the analyte.

6. The device of claim 1, wherein the analyte comprises glucose and the body fluid comprises blood.

7. The device of claim 1, wherein the first analyte quantification member comprises an assay pad containing a chemical reagent formulated to produce a color change upon reaction with the analyte.

8. The device of claim 1, wherein the device comprises a plurality of the analyte quantification members.

9. The device of claim 8, wherein the device comprises a removable cartridge containing the plurality of the analyte quantification members.

10. The device of claim 7, wherein the sensor comprises an optical sensor configured to produce signals indicative of the color change.

11. The device of claim 1, wherein the second time period is less than 1 minute.

12. The device of claim 11, wherein the second time period is 45 seconds or less.

13. The device of claim 1, wherein the signal comprises at least one of a visual signal and an audible signal.

14. The device of claim 1, further comprising at least one skin-penetration member.

15. The device of claim 8, further comprising a plurality of skin-penetration members, wherein each of the plurality of analyte quantification members has a respective skin-penetration member associated therewith.

16. The device of claim 14, wherein the at least one skin-penetration member comprises a needle having an inner lumen, and the at least one passageway comprises the inner lumen of the needle.

17. The device of claim 15, further comprising a removable cartridge containing the plurality of analyte quantification members and the plurality of skin-penetration members.

18. The device of claim 14, wherein the non-transitory memory device further comprises programmed instructions to activate the vacuum source prior to, during, or subsequent to piercing the skin with the at least one skin-penetration member.

19. The device of claim 1, wherein an anticoagulant material is provided on at least a portion of the passageway.

20. The device of claim 16, wherein an anticoagulant material is provided on at least a portion of the inner lumen.

21. The device of claim 1, further comprising a skin interface member and a skin-penetration member, wherein at least one of the skin interface member and the skin-penetration member comprises a guide element configured to guide a flow of body fluid in a desired direction toward a desired location.

22. The device of claim 21, wherein both the skin interface member and the skin-penetration member comprise a guide element.

23. The device of claim 18, wherein the non-transitory memory device comprises programmed instructions to activate the vacuum source prior to piercing the skin with the at least one skin-penetration member.

24. The device of claim 14, wherein the non-transitory memory device further comprises programmed instructions to drive the skin-penetration member into skin of the user to form the wound.

25. The device of claim 1, wherein the non-transitory memory device further comprises instructions to deactivate the vacuum source.

Description

FIELD

The present invention relates to devices, arrangements and methods involving measurements of the presence or concentration of an analyte contained in a sample of body fluid.

BACKGROUND

In this specification where a document, act or item of knowledge is referred to or discussed, this reference or discussion is not an admission that the document, act or item of knowledge or any combination thereof was at the priority date, publicly available, known to the public, part of common general knowledge, or otherwise constitutes prior art under the applicable statutory provisions; or is known to be relevant to an attempt to solve any problem with which this specification is concerned.

According to the American Diabetes Association, diabetes is the fifth-deadliest disease in the United States. Since 1987 the death rate due to diabetes has increased by 45 percent. There are an estimated 20.8 million children and adults in the United States, or 7% of the population, who have diabetes. The total annual economic cost of diabetes in 2007 was estimated to be $174 billion. This is an increase of $42 billion since 2002. This 32% increase means the dollar amount has risen over $8 billion each year.

A critical component in managing diabetes is frequent blood glucose monitoring. Currently, a number of systems exist for self-monitoring by the patient. Most fluid analysis systems, such as systems for analyzing a sample of blood for glucose content, comprise multiple separate components such as separate lancing, transport, and quantification portions. These systems are bulky, and often confusing and complicated for the user.

As a result, certain efforts have been made to develop an "integrated device" that combines the steps and mechanisms for acquiring a sample body fluid, transporting the body fluid to a measurement device, and quantifying the level of analyte contained in the sample body fluid all in a single device. Examples of such devices are illustrated in U.S. Pat. Nos. 6,540,675 and 7,004,928. Although such devices are designed to reliably obtain an adequate sample volume from the user, occasionally, for a number of different reasons, the device will be unable to successfully collect and transport an adequate sample volume for analysis on a first attempt. Devices such as those described above include a skin-penetration member, such as a needle which is driven into the surface of the skin of the user. Once the skin-penetration member has been triggered or activated, such devices typically lack the ability to be "re-cocked" so that the same skin-penetration member can be used again to pierce the surface of the skin. When an inadequate sample volume is collected and transported as a result of the initial wound creation, that particular test cannot proceed. Thus, the test is "wasted." The user must perform a new test using a fresh skin-penetration member and quantification member. This can increase the costs to the user associated with monitoring the analyte or glucose levels. Moreover, the inability to salvage a successful test from a single wound means that the user will often create a separate wound at a new sampling site, or be forced to cause further damage to the existing wound in order to collect and transport an adequate sample volume for analysis. This obviously increases the pain and frustration experienced by the user, which is counterproductive to the goal of encouraging the user to frequently and systematically monitor their analyte or glucose levels.

Therefore, there is a need in the art for providing body fluid sampling and analysis techniques and devices which offer the user greater flexibility in the collection of an adequate sample volume to present to the device for analysis.

SUMMARY

According to the present invention, there are provided constructions, arrangements and techniques that may address one or more of the above-mentioned objectives. However, the present invention is not limited to the context of blood sampling performed for the purposes of monitoring glucose concentration. Numerous alternative applications or uses for the concepts described herein are contemplated.

According to certain aspects of the present invention, there are provided devices, constructions, arrangements and techniques that may optionally provide one or more of the following benefits or advantages: notifying the user that an inadequate sample volume has been collected or transported, and providing the user with an opportunity to re-apply a sample of body fluid in order to provide the necessary sample volume for analysis.

As used herein "digital" means fingers or toes, and encompasses lancing sites on the dorsal or palm side of the distal finger tips.

As used herein, "body fluid" encompasses whole blood, intestinal fluid, and mixtures thereof, as well as urine, saliva and other fluids contained in the body.

As used herein "integrated device" or "integrated meter" means a device or meter that includes all components necessary to perform sampling of body fluid, transport of body fluid, quantification of an analyte, and display of the amount of analyte contained in the sample of body fluid.

It is to be understood that reference herein to first, second, third and fourth components (etc.) does not limit the present invention to embodiments where each of these components is physically separable from one another. For example, a single physical element of the invention may perform the functions of more than one of the claimed first, second, third or fourth components. Conversely, a plurality of separate physical elements working together may perform the functions of one of the claimed first, second, third or fourth components. Similarly, reference to first, second (etc.) method steps does not limit the invention to only separate steps. According to the invention, a single method step may satisfy multiple steps described herein. Conversely, a plurality of method steps could, in combination, constitute a single method step recited herein. In addition, the steps of the method are not necessarily limited to the order in which they are described or claimed herein. The term "and" is generally intended to include the alternative of the terms appearing on either side thereof, and does not generally require the presence of both.

According to one aspect, the present invention is directed to a method of performing an assay to determine the presence or concentration of an analyte contained in a sample of body fluid by using a device comprising at least one analyte quantification member and a sensor associated therewith, the method comprising: applying a first sample to the analyte quantification member; detecting the presence or absence of an adequate sample volume; wherein upon detection of the absence of an adequate sample volume, initiating a finite timed period, and signaling the user to introduce a second sample of body fluid to the analyte quantification member.

According to another aspect, the present invention is directed to a device for performing an assay to determine the presence or concentration of an analyte contained in a sample of body fluid, the device comprising: at least one analyte quantification member; at least one passageway in fluid communication with the at least one analyte quantification member; a sensor constructed and arranged to detect the presence or absence of an adequate sample volume applied to the at least one analyte quantification member; and a controller in signal communication with the sensor, the controller is configured and arranged such that upon detection of the absence of an adequate sample volume, the controller initiates a finite timed period and signals the user to introduce another sample of body fluid into the at least one passageway.

A device for collecting a sample of body fluid, the device comprising: a skin interface member and a skin penetration member, wherein at least one of the skin interface member and the skin penetration member comprises a guide element configured to direct the flow of body fluid in a desired direction toward a desired location.

BRIEF DESCRIPTION OF THE DRAWING FIGURES

The following description of preferred embodiments can be read in connection with the accompanying drawings in which like numerals designate like elements and in which:

FIG. 1 is a flowchart illustrating certain methods performed according to the principles of the present invention.

FIG. 2 is a front perspective view of a device formed according to other aspects of the present invention.

FIG. 3 is a cut away side view of the device of FIG. 2.

FIG. 4 is a partial sectional view of an alternative embodiment of the present invention.

FIG. 5 is a side view of an additional embodiment of the present invention.

FIG. 6 is a partial sectional view of a further embodiment of the present invention.

FIG. 7 is a partial sectional view of still another embodiment of the present invention.

FIG. 8 is a partial sectional view of an arrangement formed according to a further aspect of the present invention

FIG. 9 is a partial sectional view of an arrangement formed according to a further alternative embodiment of the present invention.

FIG. 10 is a top perspective view of the arrangement of FIG. 9.

DETAILED DESCRIPTION

According to a first aspect of the present invention, there are provided techniques for performing an assay to determine the presence and/or concentration of an analyte contained in a sample of body fluid. For example, according to the present invention, the techniques described herein can be used to analyze a sample of body fluid to quantify the amount of an analyte (e.g., glucose, bilirubin, alcohol, controlled substances, toxins, hormones, proteins, etc.) contained therein.

Exemplary methods performed according to the principles of the present invention are illustrated by the flowchart appearing in FIG. 1. The method begins with the production of a sample of body fluid. The manner in which the sample of body fluid is produced or collected is not critical to the practice of the techniques of the present invention. For example, in a situation where the methods or techniques of the present invention are practiced in the context of patient self-monitoring of blood glucose levels, or taking a blood glucose level measurements in a clinical setting, a small volume of blood can be produced by piercing the skin to create a wound at a sampling site from which the body fluid can be expressed. The sampling site that is chosen may include a digital skin surface, or an alternative sampling site such as the forearms, thighs, and the like. Thus, as indicated by the broken-line process box appearing in FIG. 1, the step of piercing the skin is optional within the context of the methods and techniques of the present invention. When practiced, the skin can be pierced by any suitable device or technique. Suitable devices and techniques include lancets, hollow needles, a burst of fluid pressure, concentrated energy (e.g., laser), and the like.

Once a sample of body fluid has been produced, it is then applied to at least one analyte quantification member. Any suitable form of analyte quantification member may be utilized. Thus, for example, the analyte quantification member can be either electrochemical or photometric in nature. According to one particular illustrative, non-limiting embodiment, the least one analyte quantification member may comprise an assay pad containing a chemical reagent which is formulated such that a color change is produced upon reaction with a target analyte, as known per se to those skilled in the art.

At least one sensor is utilized to for purpose of detecting the presence or absence of an adequate sample volume. Any suitable sensor construction or arrangement may be utilized to detect, calculate and/or estimate sample volume. Thus, for example, the sensor may be either electrochemical or photometric in nature. The sensor may be separate and not otherwise associated with the least one analyte quantification member. According to one illustrative, non-limiting example, the sensor may comprise a flow sensor which detects, and possibly quantifies, the flow of body fluid to the least one analyte quantification member. Alternatively, the least one sensor may comprise an electrochemical or optical sensor that interrogates the at least one analyte quantification member to detect the presence of the sample of body fluid, and to calculate and/or estimate the volume of the sample. According to one non-limiting example, when the at least one analyte quantification member comprises an assay pad containing a chemical reagent which changes color upon exposure to the target analyte, an optical sensor can be used to interrogate the at least one analyte quantification member and detect this color change in those areas of the assay pad which have been contacted by the body fluid sample containing the target analyte. Examples of suitable sensors which can be utilized in this manner include, but are not limited to, CCD and CMOS type sensors. The sensor can also determine or estimate the area of the assay pad which has changed color due to contact with the sample of body fluid. This area can then be used by supporting electronics to calculate and/or estimate the volume of body fluid applied to the at least one analyte quantification member. A detailed explanation of such a calculation or estimation is contained in U.S. Pat. No. 7,052,652, the entire contents of which are incorporated herein by reference.

If the sensor determines that an adequate volume of body fluid has been introduced to the least one analyte quantification member within an acceptable time frame, the assay continues with the calculation of the presence and/or amount of analyte contained within the sample of body fluid. Optionally, the user may be signaled by the device or meter that an adequate volume of sample has been detected. Any suitable audible and/or visual signal may be generated and used for this purpose. Thus, for example, a message containing alphanumeric characters and/or symbols can be generated on a display. Alternatively, a "green light" or other visual cue may be generated by any portion of a meter or device. In addition, an audible signal, such as a spoken message or audible cue may be generated instead of, or in addition to, the above mentioned visual signal. Again, any suitable technique can be utilized to detect the analyte and/or calculate its concentration. Thus, for example, both electrochemical and photometric techniques can be utilized. According to one non-limiting example, when at least one analyte quantification member comprises an assay pad containing a chemical reagent which produces a color change upon reaction with the target analyte, an optical sensor can be utilized to interrogate the at least one analyte quantification member, subsequent to the detection of an adequate sample volume, to detect to change in color produced by reaction between the target analyte and the chemical reagent. This change in color can then be correlated with a particular analyte concentration. This type of photometric analysis is known per se to those skilled in the art. Once a calculation of the amount of target analyte contained in the sample of body fluid has been performed, the results of the calculation can then be displayed for the user. Any suitable arrangement of conventional electronics and/or software components, which may include a controller, central processing unit (CPU), memory components, electrical connections, and the like, can be utilized in conjunction with the above-mentioned sensor and at least one analyte quantification member to perform the necessary calculations, and generate visual and/or audible signals.

If the sensor determines that an inadequate volume of body fluid has been introduced to the least one analyte quantification member within the above-mentioned time frame, according to the present invention steps are then taken in an attempt to salvage the assay. A second finite time period can be initiated which allows the user time to take additional steps to supply an adequate volume of body fluid. This second finite time period may comprise any suitable amount of time. According to illustrative non-limiting examples, the second finite time period can be less than one minute, or 45 seconds or less. The user may also be provided with a visual and/or audible signal to indicate that additional steps are necessary in order to apply an adequate volume of body fluid to perform the assay. This signaling may take place prior to the start of the finite time period, concurrently with the start of the finite time period, or subsequent to the start of the finite time period. Any suitable visual and/or audible signal may be utilized, as discussed above.

In response to receiving the signal to take additional steps to produce an adequate sample of body fluid, and present it to the least one analyte quantification member, any additional steps which could produce such additional sample volume may be undertaken. According to one non-limiting example, when the sample of body fluid has been produced by piercing the skin to create a wound from which body fluid can be expressed, the additional steps taken to increase the volume of the sample body fluid may include having the user apply a manual "milking" action in the vicinity of the wound. This is achieved by alternately squeezing and releasing the skin in the vicinity of the wound to express additional body fluid therefrom. This technique is well-known by people who have diabetes and regularly monitor their blood glucose levels, and is often successful in expressing a sufficient quantity of body fluid in order to perform an assay to determine blood glucose concentration.

Alternatively, some techniques and devices for producing a sample of body fluid by piercing the skin utilize some form of catalyst to increase the amount of body fluid expressed from the wound created by piercing the skin. Suitable catalysts include heat, pressure, vacuum, vibration, and topical drugs. These catalysts may be applied before, during, or after piercing the skin, or a combination of these times. According to the present invention, if an inadequate quantity of body fluid is produced after piercing the skin, upon receiving the above-mentioned signal that an inadequate sample body fluid has been detected, the user may then be instructed, or decide on their own, to administer a catalyst in the vicinity of the wound in an attempt to increase the amount of body fluid expressed therefrom, regardless of whether or not a catalyst was utilized in connection with the initial wound creation and body fluid sample extraction. Any suitable arrangement of conventional electronics and/or software components, which may include a controller, central processing unit (CPU), memory components, electrical connections, display components, and the like, can be utilized to generate visual and/or audible signals, which may include specific instructions with respect to the reapplication of a catalyst. It is comprehended within the scope of the present invention that the user may make one, or multiple attempts, to produce an adequate volume of body fluid within the second predetermined time period. If more than one attempt is made, the same technique (e.g., milking or application of a catalyst) can be repeated. Alternatively, the multiple attempts can comprise a combination of different techniques for expressing an adequate sample volume. By way of nonlimiting example, a user could attempt to milk additional body fluid from the wound one or more times, and if unsuccessful, then apply a catalyst to the wound site one or more times, all within the predetermined second time period. This technique or functionality is represented in the flow diagram appearing in FIG. 1. It should be understood that any of the techniques or methods described herein may be practiced so as to include this technique or functionality. Similarly, any device or arrangement described herein may also be constructed, or utilized, in a manner consistent with this technique or functionality.

If the sensor determines that an inadequate volume of body fluid has been introduced to the least one analyte quantification member within the above-mentioned second finite time period, the assay may be terminated. An appropriate signal may be generated to indicate to the user that the assay has been terminated, or the testing event has failed.

If the sensor determines that an adequate volume of body fluid has been introduced to the least one analyte quantification member within the above-mentioned second time period, the assay can then continue. Thus, the assay continues with the calculation of the presence and/or amount of analyte contained within the sample of body fluid. Again, any suitable technique can be utilized to detect the analyte and/or calculate its concentration. Thus, for example, both electrochemical and photometric techniques can be utilized, such as those non-limiting examples already discussed above. Once the analyte presence and/or concentration has been calculated, the results may be presented to the user by one or more of visual and audible signals.

Since body fluid such as blood may naturally attempt to coagulate upon exposure to the environment, it may be advantageous to take some measures which will permit the continued flow of body fluid after a certain period of time has elapsed. Thus, for example, a sample of body fluid may be applied to the at least one analyte quantification member which proves to have an inadequate volume. Upon detection of this inadequate volume, and with the optional signaling to the user of this condition, the additional steps discussed above may be taken in order to attempt to salvage the test. As mentioned above, these additional steps may take some period of time to complete. During the period of time which is elapsed since the first application of body fluid, the above-mentioned coagulation effect may impede or completely block the flow of additional sample which is subsequently applied. Therefore, according to the principles of the present invention, steps may be taken to prevent coagulation of the body fluid. One illustrative, non-limiting example would be to apply an anticoagulant material, at least partially, to one or more components or members within which the body fluid comes into contact. Examples of suitable anticoagulant materials may include, but are not limited to, aspirin, heparin and Coumadin.RTM..

According to further aspects of the present invention, there are provided arrangements and/or devices which are constructed and arranged to have a more flexible mode of operation and that may achieve one or more of the advantages associated with the principles of the present invention. It is to be understood that any of the arrangements and/or devices described herein may be utilized to practice the techniques or methods of the present invention which have been previously described.

One embodiment of an arrangement 10 of the type described above may be in the form of a device, as illustrated in FIGS. 2-3. As illustrated therein, the arrangement 10 may optionally be in the form of an integrated meter or device 11. It should be understood that any of the methods, arrangements and devices described herein may be practiced with an integrated meter, which may have one or more of the features of the integrated device 11 of the illustrated embodiment. However, it should be made clear that the present invention is necessarily not so limited. The methods, arrangements and devices of the present invention are applicable to a number of different devices and systems, such as simple lancing devices, meters that lack any sample creation mechanisms, multiple component systems, and the like. Similarly, the arrangements and devices described herein can be constructed and arranged to function in accordance with the methods of the present invention, but are not necessarily so limited.

The methods, arrangements and devices described herein may be used at, or applied to, a skin surface of a user at a suitable sampling site. One suitable sampling site is on a digit D. However, the methods, arrangements and devices are not necessarily so limited. For example, the methods, arrangements and devices described herein may be used or applied to any skin surface at any suitable sampling site which may include alternative sampling sites such as the forearm, thigh, etc.

According to the embodiment illustrated in FIGS. 2-3, the arrangement 10 or meter 11 includes a housing 12. The housing 12 may have any suitable shape or configuration, and is not limited to the shape and configuration illustrated. For example, the housing 12 be contoured such that it is easily grasped by the hand of the user. The housing 12 can be constructed of any suitable material. For example, the housing 12 may be constructed of a polymeric or metallic material. The housing 12 may comprise an opening 14 disposed therein. A skin interface member 16 may be disposed in the opening 14 and attached to the housing 12. The skin interface member 16 can be provided with any suitable construction, or formed from any suitable materials. For example, the skin interface member can be formed from an elastomer, silicone rubber, soft plastic, or combination of materials with different properties. A number of alternative skin interface member constructions are contemplated, as will be further described herein.

The arrangement 10 or device 11 may further optionally include a catalyst to assist in the sample acquisition process by enhancing or facilitating perfusion of body fluid at a sampling site. At least one of several catalysts may be utilized or included in the arrangement of the present invention. Possible catalysts include, heat, pressure, vacuum, vibration, and topical drugs (which induce vasodilatation and increases the blood or body fluid available at the lancing site). These catalysts may be applied before, during, after piercing of the skin, or in a combination with some or all three times, to facilitate expression of sufficient quantity of body fluid BF for determination of the concentration of an analyte (e.g., glucose) contained therein. According to the principles of the present invention, one or more of the above-described catalysts can be used in combination with each other, either concurrently or sequentially.

According to certain embodiments, a light vacuum (e.g., 3-8 in. Hg) is applied to the surface of the skin at the sampling site via opening 14, either before, during, and/or after piercing the skin. Several embodiments for applying vacuum to the wound site are contemplated. One embodiment uses a pump 18 to apply vacuum to the area of the skin via the opening 14. The pump 18 is in communication with the opening via any suitable mechanism, such as the illustrated fluid communication line 20. Alternative embodiments include using individually packaged vacuum chambers to apply vacuum, or using a syringe like mechanism to apply vacuum.

The arrangement 10 or device 11 may further comprise any suitable form of analyte quantification member 24. For example, the analyte quantification member 24 can be either electrochemical or photometric in nature. According to one particular illustrative, non-limiting embodiment, the least one analyte quantification member 24 may comprise an assay pad 26 containing a chemical reagent which is formulated such that the color changes produced upon reaction with a target analyte, as known per se to those skilled in the art. A sample of body fluid BF may be introduced to the analyte quantification member by any suitable construction or technique. For example, the sample of body fluid BF may be introduced via the opening 14 and/or passageway 22.

At least one sensor 28 may be provided in conjunction with the at least one analyte quantification member 24. Any suitable sensor 28 construction or arrangement may be provided to interrogate the at least one analyte quantification member 24. The sensor may be integrated with the analyte quantification member 24, or it may be separate and not otherwise associated therewith. For example, the analyte quantification member 24 can be analyzed by a sensor 28 that forms part of the arrangement 10 or device 11. Alternatively, the analyte quantification member 24 is removed or separate from the arrangement 10 or device 11, and inserted into an electrochemical or photometric meter.

The least one sensor 28 may comprise an electrochemical or optical sensor that interrogates the at least one analyte quantification member 24 to detect the presence of the sample of body fluid, and/or to calculate or estimate the volume of the sample. According to one non-limiting example, when the at least one analyte quantification member comprises an assay pad 26 containing a chemical reagent which changes color upon exposure to the target analyte, an optical sensor 28 can be used to interrogate the at least one analyte quantification member 24 and detect this color change in those areas of the assay pad 26 which have been contacted by the body fluid sample BF containing the target analyte. Examples of suitable optical sensors which can be utilized in this manner include, but are not limited to, CCD and CMOS type sensors. The sensor 28 can also determine or estimate the area of the assay pad which has changed color due to contact with the sample of body fluid. This area can then be used to calculate and/or estimate of the volume of body fluid applied to the at least one analyte quantification member. A detailed explanation of such a calculation or estimation is contained in U.S. Pat. No. 7,052,652, the entire contents of which are incorporated herein by reference.

The arrangement 10 or device 11 may further includes at least one skin-penetration member 30. The at least one skin-penetration member 30 can take any suitable form. For example, the at least one skin-penetration member can comprise a solid lancet or a hollow needle. Conventional arrangements often require separate mechanisms for drawing a sample of blood to the surface of the skin and for transporting the sample to a reaction chamber. The arrangements of the present invention can optionally include a skin-penetration member 30 in the form of a hollow needle having an inner lumen to both create a wound opening and transport the sample, thereby greatly simplifying and improving the effectiveness of the arrangement 10 or device 11.

According to one optional embodiment, the skin-penetration member(s) 30 can be in the form of a so-called "microneedle." As the name implies, microneedles are characterizable by their relatively small outer diameters. For example, a microneedle, as the term is utilized herein, may encompass a skin-penetration member having an outside diameter which is on the order of 40-200 .mu.m. When the microneedle is hollow and comprises an inner lumen, the inside diameter can vary. For example, having an inside diameter on the order of 25-160 .mu.m. Needles are also characterizable in the art by reference to the "gage." By way of illustration, and consistent with the above description, microneedles having a gage ranging from 26-36 are clearly comprehended by the present invention. Certain advantages may be gleaned from the use of such microneedles as the skin-penetration member. In particular, due to their small size, the size of the wound left upon entry into the skin is relatively small, thereby minimizing the pain associated with such needle insertions and allowing for a quicker healing process. However, the present invention is certainly not limited to the use of such microneedles. Thus, for example, according to one possible alternative embodiment, the skin penetration member(s) comprise hollow needles having a gage of about 20-25, or comprising hollow needles having an inner diameter of about 0.007 inches and an outer diameter of about 0.020 inches.

The at least one skin-penetration member 30 can be formed of any suitable material, such as metal, plastic, glass, etc. Optionally, the at least one skin penetration member can be in fluid communication with an analyte quantification member 24.

The at least one skin-penetration member 30, and/or the analyte quantification member 24 can be attached to an actuation element (not shown), such as a spring. The actuation element drives the at least one skin-penetration member 30 into the skin at the sampling site.

As further illustrated in FIGS. 2-3, the arrangement 10 or device 11 can comprise a plurality of skin penetration members 30 and/or analyte quantification members 24. The plurality of skin penetration members 30 and/or analyte quantification members 24 may optionally be mounted within a removable cartridge 32. Thus, the arrangement 10, particularly when in the form of an integrated device 11, is capable of performing a number of assays on collected body fluid BF samples in a fully self-contained a manner. After a number of assays have been performed which correspond to the number of skin penetration members 30 and analyte quantification members 24, the cartridge 32 can be removed, discarded, and replaced with a new cartridge.

According to certain embodiments of the present invention, the arrangement 10 can operate in an automatic or semi-automatic manner. For example, a user may place the skin interface member 16 over the surface of the skin and when the user is ready to produce a sample of body fluid and/or perform an assay, the user initiates the process by, for example, pressing a button 33, touch screen or other interface device. This can initiate a programmed sequence of events in the device which may include one or more of actuation of a catalyst, and driving the skin-penetration member 30 into the skin. At a predetermined time, the catalyst is deactivated. This mode of operation can be characterized as "semi-automatic" in that sequence of events must be manually initiated by the user.

According to one alternative, the mode of operation can be fully automatic. For example, the user places the skin interface member 16 over the skin at a suitable sampling site. The arrangement 10 or device 11 can be provided with one or more sensor 17 that detect and verify that the skin of the user is properly located over the opening 14 and ready for the sampling procedure to begin. The one or more sensor can comprise any suitable sensor, such as a capacitive touch sensor, a resistive touch sensor a dome switch, or a microswitch. Once this state has been sensed, the device automatically activates a programmed sequence of events in the device which may include one or more of activation of a catalyst, and driving the skin-penetration member 30 into the skin. At a subsequent predetermined time, the catalyst device 14 is deactivated. The catalyst device can be deactivated before, during or after the skin-penetration member is driven into the skin.

An arrangement 10 or device 11 formed according to the principles of the present invention may also include supporting electronics. Thus, for example, the arrangement 10 or device 11 may include a controller 34 which is in signal communication 36 with the sensor 28 and the optional pump 18. The controller 34 may include a central processing unit, memory, control logic (e.g., code), power supply, supporting electronics, and the like, as familiar per se to those skilled in the art. The controller 34 controls the operations of the arrangement 10 or device 11.

The controller 34, in conjunction with one or more of the features of the arrangement 10 or device 11 described herein, may be used to execute one or more of the steps of the methods described above in connection with certain aspects of the present invention. Exemplary body fluid analysis methods which may be performed in conjunction with the above-described arrangement 10 or device 11, but are not necessarily limited thereto, is described as follows.

The manner in which the sample of body fluid is produced or collected is not critical to the practice of the techniques of the present invention. For example, in a situation where the methods or techniques of the present invention are practiced in the context of patient self-monitoring of blood glucose levels, or taking a blood glucose level measurements in a clinical setting, a small volume of blood can be produced by piercing the skin to create a wound at a sampling site from which the body fluid can be expressed. The sampling site that is chosen may include a digital skin surface, or an alternative sampling site such as the forearms, thighs, and the like. Thus, when the arrangement 10 is implemented in the form of an optional integrated device (e.g., 11), the skin can be pierced by the at least one skin-penetration member 30 to create a wound in the surface of the skin from which a sample of body fluid BF can be expressed.

Once a sample of body fluid BF has been produced, it is then applied to at least one analyte quantification member 24 via the opening 14 and/or passageway 22. The sensor 28 may optionally be utilized to for purpose of detecting the presence or absence of an adequate sample volume. According to one non-limiting example, when the at least one analyte quantification member 24 comprises an assay pad 26 containing a chemical reagent which changes color upon exposure to the target analyte, an optical sensor can be used to interrogate the at least one analyte quantification member and detect this color change in those areas of the assay pad 26 which have been contacted by the body fluid sample BF containing the target analyte. This area can then be used by supporting electronics (e.g., controller 34, central processing unit, memory, control logic (e.g., code), power supply, etc.) to calculate and/or estimate of the volume of body fluid applied to the at least one analyte quantification member as previously described herein.

If the sensor 28 determines that an adequate volume of body fluid has been introduced to the least one analyte quantification member within an acceptable time frame, the controller 34 directs the assay to continue with the calculation of the presence and/or amount of analyte contained within the sample of body fluid. When at least one analyte quantification member 24 comprises an assay pad 26 containing a chemical reagent which produces a color change upon reaction with the target analyte, the sensor 28 can be utilized to interrogate the at least one analyte quantification member 24, subsequent to the detection of an adequate sample volume, to detect the change in color produced by reaction between the target analyte and the chemical reagent. This change in color can then be correlated with a particular analyte concentration. This type of photometric analysis is known per se to those skilled in the art. Once a calculation of the amount of target analyte contained in the sample of body fluid has been performed, the results of the calculation can then be visually presented on a display 38, or audibly communicated via a speaker 42, for the user.

If, as a result of the interrogation by the sensor 28, it is determined that an inadequate volume of body fluid BF has been introduced to the least one analyte quantification member 24 within the above-mentioned time frame, according to the present invention steps are then taken in an attempt to salvage the assay. A second finite time period can be initiated by the controller 34 which allows the user time to take additional steps to apply an adequate volume of body fluid. This second finite time period may comprise any suitable amount of time. According to illustrative non-limiting examples, the second finite time period can be less than one minute, or 45 seconds or less. The controller 34 may also provide the user with a visual signal 40 on the display 38, and/or audible signal via speaker 42, to indicate that additional steps are necessary in order to apply an adequate volume of body fluid to perform the assay. This signaling may take place prior to the start of the finite time period, concurrently with the start of the finite time period, or subsequent to the start of the finite time period.

In response to receiving the signal to take additional steps to produce an adequate sample of body fluid, and present it to the at least one analyte quantification member 24, any additional steps which could produce such additional sample volume may be undertaken. According to one non-limiting example, when the sample of body fluid has been produced by piercing the skin to create a wound from which body fluid can be expressed, the additional steps taken to increase the volume of the sample body fluid may include having the user or apply a manual "milking" action in the vicinity of the wound. This is achieved by alternately squeezing and releasing the skin in the vicinity of the wound to express additional body fluid therefrom. This technique is well-known by people who have diabetes and regularly monitor their blood glucose levels, and is often successful in expressing a sufficient quantity of body fluid in order to perform an assay to determine blood glucose concentration. Once additional sample has been milked from the wound, the additional or "second" sample is applied to the analyte quantification member 24 via the opening 14 and/or passageway 22.

Alternatively, if an inadequate quantity of body fluid BF is produced after piercing the skin in conjunction with a first application of a catalyst, upon receiving the above-mentioned signal that an inadequate sample body fluid has been detected, the user may then be instructed via the aforementioned signaling, or decide on their own, to administer a catalyst of in the vicinity of the wound in an attempt to increase the amount of body fluid expressed therefrom regardless of whether a catalyst was used in conjunction with initial wound creation and body fluid sample extraction. Thus, for example, when a vacuum catalyst is utilized the user may be instructed, or decide on their own, to place the skin interface member 16 over the wound and reapply the vacuum catalyst. The catalyst can be applied in any suitable manner. Thus, after placing the skin interface member 16 over the wound, the user can initiate the catalyst by pressing a button 33, touchscreen or any other suitable interface device. Alternatively, the application of the catalyst may be automatically initiated through sensing that the skin is properly located over the skin interface member 16, as described above.

If the sensor 28 determines that an inadequate volume of body fluid BF has been introduced to the least one analyte quantification member 24 within the above-mentioned second finite time frame, the assay may be terminated. An appropriate signal may be generated on the display 38 or via the speaker 42 to indicate to the user that the assay has been terminated, or the testing event has failed.

If the sensor 28 determines that an adequate volume of body fluid has been introduced to the least one analyte quantification member 24 within the above-mentioned second time frame, the assay can then continue. Thus, the assay continues with the calculation of the presence and/or amount of analyte contained within the sample of body fluid in the manner described above. Once the analyte presence and/or concentration has been calculated, the results may be presented to the user through one or more of visual and audible signals via the display 38 or speaker 42.

Since body fluid such as blood may naturally attempt to coagulate upon exposure to the environment, it may be advantageous to take some measures which will permit the continued flow of body fluid after a certain period of time has elapsed. Thus, according to one illustrative, non-limiting example an anticoagulant material may be applied, at least partially, to one or more of the opening 14, skin interface member 16, passageway 22, or any other components or members with which the body fluid comes into contact. Examples of suitable anticoagulant materials may include, but are not limited to, aspirin, heparin and Coumadin.RTM.. According to a further alternative embodiment, and additional agent or material may be applied to either the opening 14, skin interface member 16, passageway 22, or other components are members with which the body fluid comes into contact that improves the flow of body fluid. Such additional agents or materials include, for example, Silwet.RTM.. According to additional alternative embodiment, one or more of the above-mentioned parts or components of the arrangement 10 or device 11 can be coated with a combination of these two types of materials. According to one illustrative, non-limiting example, one or more of the above-mentioned parts or components are coated with a solution having a composition such as: 49.4 ml of sterile water+49.4 ml of sterile isopropyl alcohol+0.8 ml of Silwet.TM. L7600+0.46 grams of low molecular weight heparin.

Devices, arrangements and techniques according to additional optional embodiments are illustrated in FIGS. 4-10. It should be understood that the devices, arrangements and techniques of these additional alternative embodiments can be utilized in connection with the practice of any of the foregoing techniques or methods of the present invention. However, the present invention is not necessarily so limited. The devices, arrangements and techniques of these additional alternative embodiments can be utilized in connection with the practice of additional techniques or methods not described herein. Similarly, the devices, arrangements and techniques of the additional alternative embodiments of FIGS. 4-10 may possess any or all of the features and/or functionality of the previously described embodiments (e.g., FIGS. 2-3). However, these additional alternative embodiments are not so limited. The techniques, devices and arrangements depicted in FIGS. 4-10 may be successfully utilized in connection with other devices or arrangements not previously described herein. When the additional alternative embodiments depicted in FIGS. 4-10 possess features which are common to the previously described embodiments (e.g., FIGS. 2-3), the same reference numerals have been utilized to identify such common features. In the interest of conciseness, such common features may not be fully described in the following description of these additional alternative embodiments. The description of these common features contained in the embodiments depicted in FIGS. 4-10 are incorporated herein by reference to their previous description in connection with the previously-described embodiments.

FIG. 4 illustrates an arrangement 400 formed according to an optional alternative embodiment of the present invention. The arrangement 400 includes a slightly modified skin interface member 116. The skin interface member can be formed from any suitable material, such as an elastomer, silicone rubber, plastic, or combination of different materials. The skin interface member 116 may further comprise an optional rim-like formation 117. The rim-like formation 117 may provide the advantage of creating a ring of pressure along the surface of the skin applied thereto thereby facilitating the body fluid BF sample collection procedure. Regardless of whether the optional rim-like formation 117 is present, as illustrated in broken-line in FIG. 4, the skin has a tendency to sag and project downwardly into the opening our passageway 22 defined by the skin interface member 116. This sagging effect can be even more pronounced when, for example, a vacuum catalyst is applied during the course of the body fluid BF sample collection effort.

FIG. 4 depicts an attempt to apply a sample of body fluid BF to an analyte quantification member 24. The analyte quantification member 24 includes a hub 25, with a reagent pad 26 attached thereto. The skin-penetration member 30 is provided in the form of a hollow needle having an inner lumen 34. The inner lumen 34 is in fluid communication with the assay at 26. This fluid communication can be provided through a number of possible arrangements. Thus, an end of the skin-penetration member 30 can be mounted all the way through the hub so that it directly communicates with the reagent pad 26. Alternatively, an end of the skin-penetration member 30 can be mounted to the hub in a manner such that the end is based from the reagent pad 26, in which case the hub 25 may optionally be provided with a separate passage 36 communicating with the end of the skin-penetration member 30 and be at reagent pad 26.

As further illustrated in FIG. 4, and according to one alternative embodiment, once additional measures have been taken in order to obtain an additional volume of body fluid, possibly in response to an indication from a device or arrangement that an initial attempt failed to produce an adequate sample volume, the user places the skin into contact with the skin interface member 116 such that the wound created by the initial attempt is approximately located in the center of the opening defined by the skin penetration member 116. When so located, the arrangement 400 is constructed such that the end of the skin-penetration member having an opening defined by the end of the inner lumen 34 will be in close proximity to the wound, and the additional volume of body fluid BF being expressed therefrom can be brought into communication with said opening. Since the inner lumen 34 is in fluid communication with the analyte quantification member 24, including the reagent pad 26, the body fluid BF is transported to the reagent pad 26 via gravity, capillary effects, or combination of the two. As previously described herein, steps can then be taken to determine if the reapplication of body fluid BF has been successful in order to provide an adequate sample volume to conduct an assay.

FIG. 5 illustrates an arrangement 500 comprising a modified skin penetration member construction 130 designed to facilitate receiving body fluid BF applied thereto. As illustrated therein, the skin penetration member 130 is provided with an end 131 which is provided with a geometry which has been optimized to present a surface which is more likely to be successful in receiving a sample of body fluid BF applied thereto. The end 131 is not limited to the illustrated configuration, but instead may have any suitable geometric shape that increases the likelihood of capturing a drop of body fluid applied thereto. The skin penetration member 130 can be formed from any suitable material, such as those materials previously described herein in connection with the skin penetration member 30 of the previously described embodiments. Moreover, the skin penetration member 130 can have an inner lumen 34 provided with an optional body fluid BF flow enhancing feature 34c. The flow enhancing feature 34c can comprise a surface texturing or coating. When the flow enhancing feature 34c comprises a coating, it may optionally be in the form of an anticoagulant substance, such as those anticoagulant substances previously described herein. When the analyte quantification member 24 comprises a hub 25, the hub 25 can be provided with a separate passage 36 for fluid communication between the inner lumen 34 and the reagent pad 26. The passage 36 and a hub 25 may also comprise a body fluid BF flow enhancing feature 34c.

An arrangement 600 constructed according to a further alternative embodiment is depicted in FIG. 6. As illustrated therein, the skin interface member 116 is provided with a guide element 118 which is configured to promote the flow of body fluid in a desired direction, i.e. toward an open end of a hollow skin penetration member 30 defined by the end of an inner lumen 34. The guide element 118 can be formed from the same material as the rest of the skin interface member 116. Alternatively, the guide element 118 can be formed from a different material than at least part of the remainder of the skin interface member 116. Thus, for example, the guide element 118 can be formed from a polymer material which is softer and/or more flexible than the remainder of the skin interface member 116, or vice versa. The guide element 118 can be formed from, or coated with, a high visibility material thus facilitating application of a drop of body fluid BF thereto. For example, the material or coating can comprise a bright color, reflective substance, and/or fluorescent substance. Alternatively, or in addition thereto, and associated device or arrangement can include a source of light that illuminates the guide element 118. The guide element 118 can comprise an integral part of the skin interface member 116. Alternatively, the guide element 118 can comprise a separate part or component which is either permanently or really simply attached to a remaining portion of the skin interface member 116. The guide element 118 can have any suitable geometric configuration or shape. Thus, according to certain nonlimiting examples, the guide element 118 can have a conical, frustoconical, or concave dome-like shape. At least the guide element 118 of the skin interface number 116 may optionally be provided with one or more body fluid flow-enhancing features. Therefore, at least a portion of the guide element 118 can be provided with a suitable coating 120 that promotes the flow of body fluid BF in a desired direction, toward a desired location. Coating 120 can comprise a hydrophilic coating, a hydrophobic coating, an anticoagulant coating, or combinations thereof. Alternatively, or in addition thereto, the guide element 118 may comprise a surface texturing, such as one or more capillary grooves 122 that also serve to promote the flow of body fluid in a desired direction, toward a desired location. As illustrated in FIG. 6, the coating 120 and grooves 122 can be utilized in combination with one another. Alternatively, the guide element 118 may comprise either a coating 120 or grooves 122 alone. As evident from the arrangement 600 depicted in FIG. 6, the provision of the guide element 118 is beneficial in that it permits a user some latitude in terms of how precisely the wound needs to be located relative to the position of the skin penetration member 30. The guide element 118 is configured such that if the body fluid BF is introduced onto any portion thereof, its flow is directed toward the end of the lumen 34 of the skin penetration member 30. It should be understood that the presence of a hollow needle type skin penetration member 30 is optional. Thus, for example, the arrangement 600 may be configured such that the guide element 118 directs the flow of body fluid BF directly to an analyte quantification member in fluid flow communications therewith. According to a further example, the guide element 118 can direct the flow of body fluid BF to another member or element, such as a hollow tube or similar fluid conveying or receiving structure.

FIG. 7 illustrates a further alternative arrangement 700 formed according to a further optional embodiment of the present invention. The arrangement 700 is similar to the previously described arrangement 600, except that a guide element 124 is associated with a skin penetration member 30. The guide element 124 can have the same construction, functionality and features as the guide element 118 described above. The guide element 124 can be associated with the skin penetration member 30 in any suitable fashion. According to the illustrated example, the guide element 124 is associated with the skin penetration member 30 via a collar-like portion 126, which surrounds at least a portion of the outer periphery of the skin penetration member 30. The guide element 124 can be integrally formed with the collar-like portion 126. Alternatively, the guide element 124 can be separately formed and attached in a permanent or releasable manner to the collar-like portion 126. When the analyte quantification member 24 includes a hub 25, the collar-like portion 126 can be connected to the hub 25 in any suitable manner, such as adhesively secured thereto. Alternatively, the collar-like portion 126 and the hub 25 can be integrally formed together as a single piece of the same material, or co-molded together to form a unitary structure. The guide element 124 of the arrangement 700 may perform an additional function, namely, act as a stop or limit for the depth of penetration of the skin penetration member 30 into the skin at the site of the wound. As previously described herein, the skin penetration member 30 can be actuated or driven into the surface of the skin located within the passage 22 of the skin interface member 16, thereby creating the wound. As illustrated in FIG. 7, the guide element 124 projects outwardly and upwardly relative to the skin penetration member 30. Thus, the uppermost surface of the guide element 124 can be configured and dimensioned such that it makes a desired degree of contact with the skin of a user. This contact can serve to limit the depth by which the skin penetration member may extend into the surface of the skin of the user. As described above in connection with the arrangement 600, it should be understood that the presence of a hollow needle type skin penetration member 30 is optional. Thus, for example, the arrangement 700 may be configured such that the guide element 124 directs the flow of body fluid BF directly to an analyte quantification member in fluid flow communications therewith. According to a further example, the guide element 124 can direct the flow of body fluid BF to another member or element, such as a hollow tube or similar fluid conveying or receiving structure.

FIG. 8 illustrates an alternatively constructed skin penetration member/guide element construction. As illustrated therein, the guide element 124' and the collar-like portion 126' can be formed from separate materials having distinct properties. The guide element 124' and the collar-like portion 126' may be separately formed and permanently or releasable joined together, or co-molded together to form a unitary structure. Thus, for example, the guide element 124' can be formed from a softer or more flexible material than the collar-like portion 126'. This construction may have the benefit of providing a more compliant guide element 124' for easier interfacing with the user, while the more rigid collar-like portion 126' provides for accurate location which is not easily misaligned.

FIGS. 9-10 are directed to yet another alternative arrangement 900 formed according to certain optional aspects of the present invention. The arrangement 900 has a construction similar to that of previously described arrangements 700, 800; however, according to the arrangement 900, both the skin interface member 116 and the skin penetration member 30 have guide elements 118, 124 associated therewith, respectively. The guide elements 118, 124 can have the same features, construction and functionality of the previously described embodiments. As described above in connection with the previous arrangements, it should be understood that the presence of a hollow needle type skin penetration member 30 is optional. Thus, for example, the arrangement 900 may be configured such that the guide elements 118, 124 direct the flow of body fluid BF directly to an analyte quantification member in fluid flow communications therewith. According to a further example, the guide elements 118, 124 can direct the flow of body fluid BF to another member or element, such as a hollow tube or similar fluid conveying or receiving structure.

Numbers expressing quantities of ingredients, constituents, reaction conditions, and so forth used in this specification are to be understood as being modified in all instances by the term "about." Notwithstanding that the numerical ranges and parameters setting forth, the broad scope of the subject matter presented herein are approximations, the numerical values set forth are indicated as precisely as possible. Any numerical value, however, inherently contains certain errors necessarily resulting from the standard deviation found in their respective measurement techniques. None of the elements recited in the appended claims should be interpreted as invoking 35 U.S.C. .sctn.112, 6, unless the term "means" is explicitly used.

Although the present invention has been described in connection with preferred embodiments thereof, it will be appreciated by those skilled in the art that additions, deletions, modifications, and substitutions not specifically described may be made without departing from the spirit and scope of the invention as defined in the appended claims.

* * * * *